BeiGene Ltd

BGNE

Equity

ISIN null / Valor 30165310

NASDAQ (2025-11-20)

USD 349.29-1.27%

BeiGene Ltd
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

BeiGene Ltd is a publicly traded global oncology company with a market capitalization of approximately $23 billion and a global workforce of over 10,000 employees. The company has a presence in Asia, Australia, Europe, Latin America, and North America, with administrative offices in Basel, Beijing, and Cambridge, Mass. BeiGene is known for its growing portfolio of oncology treatments in various stages of development, with a focus on innovative and accessible medicines for cancer patients worldwide. The company collaborates with biopharmaceutical companies to develop and commercialize cancer therapies, and has a strong research team working on a broad pipeline of potential treatments. One of BeiGene's key products is BRUKINSA, a small molecule inhibitor of Bruton’s tyrosine kinase, approved for the treatment of various B-cell malignancies in 70 markets globally. Co-founded by John V. Oyler in 2010, BeiGene is dedicated to addressing a wide range of cancers and making a positive impact in the field of oncology.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue Increases

Total product revenue reached $554 million in Q2 2023, an 82% increase from Q2 2022, primarily fueled by higher sales of BRUKINSA worldwide.

BRUKINSA Sales Surge

Global sales of BRUKINSA totaled $308 million, a 139% rise year-over-year and a 46% increase from the previous quarter, reinforcing its status as the leading BTK inhibitor in the market.

Improved Financial Metrics

BeiGene reported a reduced net loss of $381.1 million for Q2 2023, down from $565.7 million in the same quarter last year, attributed to higher revenues surpassing operating expense growth.

Regulatory and Pipeline Developments

The company received positive regulatory opinions and held an investor R&D Day, highlighting ongoing clinical advancements and strategic partnerships aimed at expanding their treatment options.

Summarized from source with an LLMView Source

Key figures

79.8%1Y

72.0%3Y

22.9%5Y

Performance

50.2%1Y

47.2%3Y

58.1%5Y

Volatility